Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes

Matthias Pfeifer, Bing Zheng, Tabea Erdmann, +23

Leukemia

Lymphoid NeoplasiaMalignant Blood DisorderImmunologyPathologyAutoimmunity +5

Chromatin conformation analysis of primary patient tissue using a low input Hi-C method

Noèlia Díaz, Kai Kruse, Tabea Erdmann, +4

Nature Communications

Low AmountsMolecular BiologyHi-c LibrariesChromatin Conformation AnalysisEpigenetics +17

Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL

Tabea Erdmann, Pavel Klener, James T. Lynch, +22

Blood

Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma

André Weilemann, Michael Grau, Tabea Erdmann, +19

Blood

B-cell receptor–driven MALT1 activity regulates MYC signaling in mantle cell lymphoma

Beiying Dai, Michael Grau, Mélanie Juilland, +27

Blood

Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age

Birgit Burkhardt, Ulf Michgehl, Jonas Rohde, +33

Nature Communications

Molecular profiling of EBV associated diffuse large B-cell lymphoma

Fabian Frontzek, Annette M. Staiger, Ramona Wullenkord, +18

Leukemia

Safeguard function of PU.1 shapes the inflammatory epigenome of neutrophils

Josephine Fischer, Carolin Walter, Alexander Tönges, +12

Nature Immunology

InflammationGranulocyteImmunologyImmune RegulationChronic Inflammation +6

Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma

Fabian Frontzek, Annette M. Staiger, Myroslav Zapukhlyak, +41

Nature Communications

CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas

Mélanie Juilland, Montserrat Gonzalez, Tabea Erdmann, +8

Blood